Merck News (NYSE:MRK)

DateTimeSource
Headline
10/21/20172:00PMBWReal-World Study Shows ZEPATIER® (Elbasvir & Grazoprevir) Resulted in High Rates of Sustained Virologic Response in Patients...
Observational Analysis Evaluated Patients in U.S. Veterans Affairs System Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from a retrospective database analysis of patients with chronic hepatitis C virus (HCV) genotype (GT) 1 or 4 infection who have chronic... More...>>
10/20/20175:23PMDJNMerck to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
By Peter Loftus Merck & Co. said Friday it is laying off about 1,800 U.S. sales representatives, or nearly 7% of the drugmaker's U.S. workforce, in a reorganization the company says will cut costs and shift focus to products with growth potential. Merck is eliminating three sales teams comprising reps who promote... More...>>
10/19/20179:00AMBWMerck Foundation Launches Five-Year Initiative to Improve Diabetes Care for Vulnerable and Underserved U.S. Communities
The Merck Foundation (the Foundation) has launched a five-year initiative: Bridging the Gap: Reducing Disparities in Diabetes Care (Bridging the Gap) to help improve diabetes care and health outcomes for vulnerable and underserved populations in the United States. With $16 million in funding from the Foundation over five... More...>>
10/19/20173:02AMDJNChenault Among Few Black CEOs -- WSJ
By John Simons This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal (October 19, 2017). And then there were three. Kenneth Chenault's retirement from the chief executive post at American Express Co. will reduce... More...>>
10/18/20177:53PMDJNAmex Retirement Shines Light on Lack of Diversity in CEO Ranks
By John Simons And then there were three. Kenneth Chenault's retirement from the chief executive post at American Express Co. will reduce the number of African-American CEOs of Fortune 500 companies by a quarter. The sunsetting of Mr. Chenault's career occurs as many large companies are showing great concern... More...>>
10/18/20176:55AMBWU.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review
LYNPARZA Has the Potential to Offer a New Treatment Option for Patients with Germline BRCA-Mutated, HER2-Negative Metastatic Breast Cancer Regulatory Submission Acceptance Is the First for a PARP Inhibitor Beyond Ovarian Cancer AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today... More...>>
10/18/20176:45AMBWMerck’s KEYTRUDA® (pembrolizumab) More Than Doubled Median Overall Survival Compared to Chemotherapy After Two Years of Fo...
Data Showed Median Overall Survival of 30.0 Months for KEYTRUDA Group Compared to 14.2 Months for Chemotherapy Group Findings from KEYNOTE-024 to Be Presented at World Conference on Lung Cancer Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of updated overall survival... More...>>
10/12/20171:00PMBWMerck Makes $3 Million Charitable Donation to Support Swim Across America
Merck’s Contribution Will Help Swim Across America Raise $100 Million for Cancer Research Over the Next Decade Merck Employees to Conduct Their Own “Swim Across America” Starting in 2018 To help support innovation in cancer research, Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced... More...>>
10/12/20176:55AMBWMerck Joins with the American Liver Foundation to Educate U.S. Veterans on Chronic Hepatitis C Virus (HCV) Infection
Events Across the Country Will Raise Awareness of Veterans’ Increased Risk for Chronic HCV Infection Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced a collaboration with the American Liver Foundation to raise awareness among U.S. veterans about their increased risk for chronic... More...>>
10/11/20175:30PMDJNEbola Vaccines Show Promise in New Study
By Thomas M. Burton The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease. The research, by doctors from the U.S. and Liberian governments... More...>>
10/11/20174:45PMBWMerck Provides Update on Anacetrapib Development Program
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, today announced that the company will not submit applications for regulatory approval for anacetrapib, Merck’s investigational cholesteryl ester transfer protein (CETP) inhibitor. The decision follows a thorough review of the clinical profile of anacetrapib... More...>>
10/10/20178:00AMBWSix-year Efficacy Data for GARDASIL® 9 Presented at EUROGIN 2017 Congress
Merck’s 20-year commitment to HPV research highlighted in oral session Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced results from final analyses of the pivotal Phase III efficacy, immunogenicity, and safety clinical trial for GARDASIL® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant... More...>>
10/04/20178:00AMBWMerck Highlights Ongoing Commitment to Fighting Infectious Diseases With 40 Data Presentations at ID Week 2017
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will provide 40 scientific data presentations on the company’s established and investigational infectious disease medicines and vaccines at ID Week 2017 in San Diego from Oct. 4-8. Antimicrobial research remains an... More...>>
10/03/20176:55AMBWMerck to Present New Data on ZEPATIER® (elbasvir & grazoprevir) for the Treatment of Chronic Hepatitis C Virus Infection at ...
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that data from the company’s chronic hepatitis C clinical development programs and real-world studies are scheduled to be presented at The Liver Meeting® 2017. These data presentations include new analyses of ZEPATIER® (elbasvir... More...>>
09/29/20179:33AMDJNMerck Abandons New Hepatitis C Drugs Amid Crowded Market
By Cara Lombardo Merck & Co. is halting development of new hepatitis C treatments after reviewing their effectiveness and determining an abundance of treatments, including its own drug, Zepatier, were already available. The market to treat the liver disease afflicting 3.5 million Americans has become increasingly competitive... More...>>
09/29/20176:55AMBWMerck Discontinues MK-3682B and MK-3682C Development Programs
Company to Focus on Maximizing the Potential of ZEPATIER® (Elbasvir and Grazoprevir) Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced its strategic decision to discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/ uprifosbuvir) and... More...>>
09/29/20176:55AMBWNew and Updated Clinical Data on Merck’s KEYTRUDA® (pembrolizumab) to Be Presented at 18th World Conference on Lung Cancer
Data to Include Findings from Studies Evaluating KEYTRUDA as Monotherapy, in Novel Combinations, and in Real-World Setting Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new and updated data investigating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, across multiple... More...>>
09/28/20179:00AMBWMSD Animal Health Extends Commitment to Fighting Rabies in the World’s Most At-Risk Regions
Africa and India Still Bear Highest Burden of Annual Rabies Deaths Today marks the midway milestone for World Rabies Day, when the Global Alliance for Rabies Control, together with health organizations from around the world, set a goal of eliminating human rabies transmitted by dogs by 2030. MSD Animal Health (known as... More...>>
09/28/20179:00AMBWMerck Animal Health Extends Commitment to Fighting Rabies in the World’s Most At-Risk Regions
Africa and India Still Bear Highest Burden of Annual Rabies Deaths Today marks the midway milestone for World Rabies Day, when the Global Alliance for Rabies Control, together with health organizations from around the world, set a goal of eliminating human rabies transmitted by dogs by 2030. Merck Animal Health (known... More...>>
09/27/20176:45AMBWMerck to Hold Third-Quarter 2017 Sales and Earnings Conference Call on October 27
Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2017 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Friday, Oct. 27. During the call, company executives will provide an overview of Merck’s performance for the quarter. Investors... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20171022 19:11:32